Skip to main content

Advertisement

SpringerLink
Log in

Vaccine immunotherapy for prostate cancer: from mice to men

  • IMMUNOLOGY AT THE UNIVERSITY OF IOWA
  • Published:
Immunologic Research Aims and scope Submit manuscript

Abstract

Preclinical studies demonstrated the ability of an adenovirus/PSA (Ad/PSA) vaccine to induce strong anti-PSA immune responses, and these responses were capable of destroying prostate-specific antigen (PSA)-secreting mouse prostate tumors. A series of preclinical studies have demonstrated the superiority of the Ad/PSA vaccine to other PSA vaccines for the induction of anti-PSA immune responses, the ability of Ad/PSA vaccination combined with cytokine gene therapy and the TLR9 agonist CpG to enhance the anti-prostate tumor immunotherapy, and the reduction of negative regulatory elements when the vaccine was combined with 5-fluoruracil administration. A phase I clinical trial of the Ad/PSA vaccine in men with metastatic castrate-resistant prostate cancer demonstrated the safety of the vaccine even at the highest single dose permitted by the FDA. Currently, a phase II trial of the Ad/PSA vaccine is underway treating patients in two protocols. Thus far 81 patients have been enrolled and vaccinated. Early results from the patients evaluated to date demonstrated the induction of anti-PSA T cell responses, and the majority of patients evaluated at this time had demonstrated an increase in PSA doubling times.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Siegel R, et al. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29.

    Article  PubMed  Google Scholar 

  2. Heidenreich A, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol. 2011;59(1):61–71.

    Article  PubMed  Google Scholar 

  3. Thompson I, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007;177(6):2106–31.

    Article  PubMed  Google Scholar 

  4. Gaztanaga M, Crook J. Androgen deprivation therapy: minimizing exposure and mitigating side effects. J Natl Comp Cancer Netw. 2012;10(9):1088–95 quiz 1088, 1096.

    CAS  Google Scholar 

  5. de Bono JS, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147–54.

    Article  PubMed  Google Scholar 

  6. Tannock IF, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–12.

    Article  CAS  PubMed  Google Scholar 

  7. Attard G, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol. 2009;27(23):3742–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. Nadal R, Taplin ME, Bellmunt J. Enzalutamide for the treatment of prostate cancer: results and implications of the AFFIRM trial. Future Oncol. 2014;10(3):351–62.

    Article  CAS  PubMed  Google Scholar 

  9. Lubaroff DM. Prostate cancer vaccines in clinical trials. Expert Rev Vaccines. 2012;11(7):857–68.

    Article  CAS  PubMed  Google Scholar 

  10. Buckwalter MR, Srivastava PK. “It is the antigen(s), stupid” and other lessons from over a decade of vaccitherapy of human cancer. Semin Immunol. 2008;20(5):296–300.

    Article  CAS  PubMed  Google Scholar 

  11. Elzey BD, et al. Immunization with type 5 adenovirus recombinant for a tumor antigen in combination with recombinant canary pox virus (ALVAC) cytokine gene delivery induces destruction of established prostate tumors. Int J Cancer. 2001;94(6):842–9.

    Article  CAS  PubMed  Google Scholar 

  12. Karan D, Krieg AM, Lubaroff DM. Paradoxical enhancement of CD8 T cell-dependent anti-tumor protection despite reduced CD8 T cell responses with addition of a TLR9 agonist to a tumor vaccine. Int J Cancer. 2007;121(7):1520–8.

    Article  CAS  PubMed  Google Scholar 

  13. Lubaroff DM, et al. Decreased cytotoxic T cell activity generated by co-administration of PSA vaccine and CpG ODN is associated with increased tumor protection in a mouse model of prostate cancer. Vaccine. 2006;24(35–36):6155–62.

    Article  CAS  PubMed  Google Scholar 

  14. Geary SM, et al. Tumor immunotherapy using adenovirus vaccines in combination with intratumoral doses of CpG ODN. Cancer Immunol Immunother CII. 2011;60(9):1309–17.

    Article  CAS  PubMed  Google Scholar 

  15. Madan RA, et al. Clinical evaluation of TRICOM vector therapeutic cancer vaccines. Semin Oncol. 2012;39(3):296–304.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. Kuriyama S, Tominaga K, Kikukawa M, Nakatani T, Tsujinoue H, Yamazaki M, Nagao S, Toyokawa Y, Mitoro A, Fukui H. Inhibitory effects of human sera on adenovirus-mediated gene transfer into rat liver. Anticancer Res. 1998;18:2345.

    CAS  PubMed  Google Scholar 

  17. Siemens DR, et al. Cutting edge: restoration of the ability to generate CTL in mice immune to adenovirus by delivery of virus in a collagen-based matrix. J Immunol. 2001;166(2):731–5.

    Article  CAS  PubMed  Google Scholar 

  18. Joshi VB, Geary SM, Salem AK. Biodegradable particles as vaccine antigen delivery systems for stimulating cellular immune responses. Hum Vaccin Immunother. 2013;9(12):2584–90.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. Lubaroff DM, et al. Clinical protocol: phase I study of an adenovirus/prostate-specific antigen vaccine in men with metastatic prostate cancer. Hum Gene Ther. 2006;17(2):220–9.

    Article  CAS  PubMed  Google Scholar 

  20. Lubaroff DM, et al. Phase I clinical trial of an adenovirus/prostate-specific antigen vaccine for prostate cancer: safety and immunologic results. Clin Cancer Res. 2009;15(23):7375–80.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  21. Halabi S, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol. 2003;21(7):1232–7.

    Article  PubMed  Google Scholar 

  22. Drake CG, et al. Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell. 2005;7(3):239–49.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  23. Mercader M, et al. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci USA. 2001;98(25):14565–70.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  24. Roden AC, et al. Augmentation of T cell levels and responses induced by androgen deprivation. J Immunol. 2004;173(10):6098–108.

    Article  CAS  PubMed  Google Scholar 

  25. Sutherland JS, et al. Activation of thymic regeneration in mice and humans following androgen blockade. J Immunol. 2005;175(4):2741–53.

    Article  CAS  PubMed  Google Scholar 

  26. Bronte V, Mocellin S. Suppressive influences in the immune response to cancer. J Immunother. 2009;32(1):1–11.

    Article  PubMed  Google Scholar 

  27. Geary SM, et al. The combination of a low-dose chemotherapeutic agent, 5-fluorouracil, and an adenoviral tumor vaccine has a synergistic benefit on survival in a tumor model system. PLoS One. 2013;8(6):e67904.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, University of Iowa, 375 Newton Road, Iowa City, IA, 52242, USA

    David M. Lubaroff, Daniel Vaena, James A. Brown, Erica Brown, Kenneth Nepple, Ambika Kattula & Richard D. Williams

  2. Department of Microbiology, University of Iowa, Iowa City, IA, 52242, USA

    David M. Lubaroff

  3. Department of Internal Medicine, University of Iowa, Iowa City, IA, 52242, USA

    Daniel Vaena

  4. Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, 52242, USA

    David M. Lubaroff, Daniel Vaena, James A. Brown, Pamela Zehr, Kenneth Nepple & Richard D. Williams

  5. Department of Veterans Affairs Medical Center, Iowa City, IA, 52240, USA

    Daniel Vaena, James A. Brown, Karen C. Griffith, Julie Eastman & Kenneth Nepple

Authors
  1. David M. Lubaroff
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel Vaena
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. James A. Brown
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Pamela Zehr
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Karen C. Griffith
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Erica Brown
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Julie Eastman
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Kenneth Nepple
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ambika Kattula
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Richard D. Williams
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David M. Lubaroff.

Additional information

Richard D. Williams is deceased.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lubaroff, D.M., Vaena, D., Brown, J.A. et al. Vaccine immunotherapy for prostate cancer: from mice to men. Immunol Res 59, 229–235 (2014). https://doi.org/10.1007/s12026-014-8531-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12026-014-8531-2

Keywords

Search

Navigation